{
event: "article_read",
name: `Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing`,
author: ``,
tags: `Onkologi | Hudkreft | ALL MATERIELL | Terapiområde | Kutan plateepitelkarsinom | Libtayo | Onkologi`,
publication_date: ``,
interaction_type: "content"
}
Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing
Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing
Danny Rischin,1 Michael R Migden,2 Annette M Lim,1 Chrysalyne D Schmults,3 Nikhil I Khushalani,4 Brett G M Hughes,5 Dirk Schadendorf,6 Lara A Dunn,7 Leonel Hernandez-Aya,8 Anne Lynn S Chang,9 Badri Modi,10 Axel Hauschild,11 Claas Ulrich,12 Thomas Eigentler,13 Brian Stein,14 Anna C Pavlick,15 Jessica L Geiger,16 Ralf Gutzmer,17 Murad Alam,18 Emmanuel Okoye,19 Melissa Mathias,20 Vladimir Jankovic,20 Elizabeth Stankevich,20 Jocelyn Booth,21 Siyu Li,21 Israel Lowy,20 Matthew G Fury,20 Alexander Guminski22
Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis
Denne nettsiden inneholder informasjon som er kun for helsepersonell som lege, tannlege, offentlig godkjent sykepleier, farmasøyt, optiker, tannpleier, samt studenter i disse fag.
